Japan Tissue Engineering Full Year 2025 Earnings: JP¥6.28 loss per share (vs JP¥3.52 profit in FY 2024)

Simply Wall St

May 01, 2025

Japan Tissue Engineering (TSE:7774) Full Year 2025 Results

Key Financial Results

Revenue: JP¥2.46b (down 2.3% from FY 2024).
Net loss: JP¥255.0m (down by 278% from JP¥143.0m profit in FY 2024).
JP¥6.28 loss per share (down from JP¥3.52 profit in FY 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Japan Tissue Engineering. Read for free now.

earnings-and-revenue-growth — TSE:7774 Earnings and Revenue Growth May 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Japan Tissue Engineering Earnings Insights

Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Japan.

Performance of the Japanese Biotechs industry.

The company's shares are down 1.1% from a week ago.

Risk Analysis

Be aware that Japan Tissue Engineering is showing 1 warning sign in our investment analysis that you should know about...

If you're looking to trade Japan Tissue Engineering, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.